Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SelectX Pharmaceuticals Inc.

www.selectxpharm.com

Latest From SelectX Pharmaceuticals Inc.

Stem Cell System Shows How Gene Silencing Causes Fragile X Syndrome

Using stem cells, researchers have shown that the gene mutation that causes fragile X leads to gene silencing through the binding of a small repeat mRNA transcript to the gene itself. They further show that a small molecule can disrupt this RNA-DNA duplex, preventing the disease from occurring and suggesting a potential prenatal therapy.

BioPharmaceutical Research & Development

Deals of the Week: Is Astex Settling For An Underpriced Buyout?

A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.

BioPharmaceutical United States

Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership

Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.

BioPharmaceutical Japan

Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership

Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SelectX Pharmaceuticals Inc.
  • Senior Management
  • Michael Chaparian, PhD, CEO & CSO
    Mark Nedelman, Sr. Dir., Bus. Dev.
  • Contact Info
  • SelectX Pharmaceuticals Inc.
    Phone: (508) 798-0216
    One Innovation Dr.
    3 Biotech
    Worcester, MA 01605
    USA
UsernamePublicRestriction

Register